Sestrin 2 confers primary resistance to sorafenib by simultaneously activating AKT and AMPK in hepatocellular carcinomaJimin Dai(Air Force Engineering University), Jingyao Dai(Air Force Engineering University)Cancer MedicineOctober 11, 201810.1002/cam4.1826Cited by 50SaveCiteExport RISWatch citationsRelated PapersThe interaction of HAb18G/CD147 with integrin α6β1 and its implications for the invasion potential of human hepatoma cells|BMC Cancer|2009|69Blockade of mIL‐6R alleviated lipopolysaccharide‐induced systemic inflammatory response syndrome by suppressing NF‐κB‐mediated Ccl2 expression and inflammasome activation|MedComm|2022|9Inhibition of mu-opioid receptor suppresses proliferation of hepatocellular carcinoma cells via CD147-p53-MAPK cascade signaling pathway.|PubMed|2021|8